APCER Pharma's revenues grew by more than 40% in 2013

Published on April 28, 2014 at 5:05 AM · No Comments

APCER Pharma, the truly global provider of strategic and outsourced services for clinical safety, pharmacovigilance, medical affairs, and regulatory operations, announced today that revenues grew by more than 40% in 2013 compared to the previous year. The privately held company, which ended its fiscal year on March 31, gained eight new clients during the period and now serves 5 of the Top 20 global pharmaceutical companies.

"Our strong growth was driven by a good balance of existing clients expanding our role and new companies requiring our global expertise," said Suneet Walia, President and Chief Executive Officer of APCER Pharma Solutions, Inc., the group's US division. "We will continue to empower our teams to deliver high quality, cost-effective compliance while we expand our size and scope to meet increased demand."

APCER Pharma is the only drug safety specialty firm with in-house operations on three continents. Its 24x7 Integrated Response Center maintains regulatory intelligence and submits safety-related reports on behalf of its clients in more than 100 countries. With increases in staff and enhanced infrastructure, the Integrated Response Center now has the capability to receive adverse events and medical inquiries from more than 70 countries.

During the past fiscal year, APCER Pharma doubled its existing office space in Asia and added a new operations center in the region. Plans were also finalized to move its Americas offices to a larger space near its current location in Princeton, New Jersey, tripling its capacity for growth in safety and medical information. Altogether, more than 60 staff members were added in the UK, the US and Asia during fiscal year 2013.

APCER's growth rate was notable in a variety of service areas, including:

  • Integrated, end-to-end safety and medical information solutions for global organizations and specialty pharmaceutical companies
  • Regulatory/medical writing, including investigator brochures, clinical study reports, and other submission-related documents
  • Medical Affairs, supporting field scientific staff with training and medical communications
  • Pharmaceutical risk management, including aggregate reports, risk management plans, risk management summaries, and benefit-risk assessments
Source:

APCER Pharma

Posted in: Business / Finance

Tags: ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post